DocGo vs Viemed Healthcare
DCGO and VMD side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DCGO and VMD compare
Viemed Healthcare is the larger company, worth 15 times as much as DocGo ($368M against $24.4M).
Viemed Healthcare grew revenue faster over the last twelve months (25.2% versus −32.4% for DocGo).
Viemed Healthcare keeps more of each dollar of sales as profit, with a net margin of 4.8% compared with −65.3% at DocGo.
Viemed Healthcare scores higher on the StockData Score (17 against 6 for DocGo), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DCGO | VMD |
|---|---|---|
| Size and price | ||
| Market cap | $24.4M | $368M |
| Share price | $0.247 | $9.67 |
| Change, 1 year | −77.1% | 47.9% |
| Change, 5 years | −97.6% | 59.0% |
| Beta (5Y) | 1.27 | 0.57 |
| Employees | 3,600 | 1,382 |
| StockData Score | ||
| Total score | 6 | 17 (better) |
| Valuation score | 3 | 4 (better) |
| Growth score | 0 | 5 (better) |
| Performance score | 0 | 3 (better) |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 26.9× |
| P/S | 0.1× (better) | 1.2× |
| P/B | 0.2× (better) | 2.6× |
| EV/EBITDA | – | 9.5× |
| P/FCF | – | 12.6× |
| PEG | – | 0.83 |
| FCF yield | −106% | 7.9% (better) |
| Fair value | $2.92 | $10.78 |
| Margin of safety | 91.6% (better) | 10.3% |
| Growth | ||
| Revenue growth (TTM) | −32.4% | 25.2% (better) |
| Revenue growth, 5Y average | 27.9% (better) | 15.5% |
| Net income growth (TTM) | – | 3.7% |
| EPS growth (TTM) | – | 5.9% |
| EPS growth, 5Y average | – | −13.9% |
| Profitability | ||
| Gross margin | – | 57.5% |
| Operating margin | −62.2% | 7.5% (better) |
| Net margin | −65.3% | 4.8% (better) |
| FCF margin | −8.8% | 9.7% (better) |
| Return on equity | −92.4% | 10.2% (better) |
| Return on invested capital | −101% | 12.2% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.05 |
| Net debt / EBITDA | – | −0.09 |
| Current ratio | 1.66 (better) | 1.13 |
| Altman Z-score | −2.80 | 6.42 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | 5.0% (better) |
| Shareholder yield | 0.00% | 5.0% (better) |
| Ownership | ||
| Held by institutions | 38.5% | 71.3% |
| Held by insiders | 9.8% | 15.4% |
| Insider net buying, 12 months | −$15.3K (better) | −$1.6M |
| Short interest, % of float | 2.2% | 4.9% |
Go deeper
- DCGO stock overview
- DCGO income statement
- DCGO valuation and score
- VMD stock overview
- VMD income statement
- VMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.